{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:51:13Z","timestamp":1792633873367,"version":"4.5.0"},"reference-count":316,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/35\/D\/NZ3\/03512"],"award-info":[{"award-number":["2019\/35\/D\/NZ3\/03512"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115184","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T15:49:22Z","timestamp":1690386562000},"page":"115184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Drugs targeting adenosine signaling pathways: A current view"],"prefix":"10.1016","volume":"165","author":[{"given":"Barbara","family":"Kutryb-Zaj\u0105c","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Kawecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khrystyna","family":"Nasadiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Braczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Stawarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Caiazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Kosza\u0142ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Cicala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115184_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/2398212818817494","article-title":"Purine and purinergic receptors","volume":"2","author":"Burnstock","year":"2018","journal-title":"Brain Neurosci. Adv."},{"key":"10.1016\/j.biopha.2023.115184_bib2","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.3390\/molecules25204652","article-title":"Therapeutic perspectives of adenosine deaminase inhibition in cardiovascular diseases","volume":"25","author":"Kutryb-Zajac","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.115184_bib3","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/ijms15022024","article-title":"Adenosine receptors: expression, function and regulation","volume":"15","author":"Sheth","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3390\/ijms19030784","article-title":"The inside story of adenosine","volume":"19","author":"Camici","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib5","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1152\/japplphysiol.00350.2015","article-title":"Hypoxia 2015: Beneficial and detrimental role of adenosine signaling in diseases and therapy","volume":"119","author":"Liu","year":"2015","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.biopha.2023.115184_bib6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1124\/mol.105.011783","article-title":"Adenosine in tissue protection and tissue regeneration","volume":"67","author":"Linden","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/2159-8290.CD-14-0341","article-title":"Targeting cancer-derived adenosine: new therapeutic approaches","volume":"4","author":"Young","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2023.115184_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030785","article-title":"Focusing on adenosine receptors as a potential targeted therapy in human diseases","volume":"9","author":"Effendi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2023.115184_bib9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/jphp.12720","article-title":"Safety issues of compounds acting on adenosinergic signalling","volume":"69","author":"Schmidt","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","article-title":"International union of basic and clinical pharmacology. CXII: adenosine receptors: a further update","volume":"74","author":"Ijzerman","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2023.115184_bib11","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1111\/jcmm.13864","article-title":"Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms","volume":"22","author":"Kutryb-Zajac","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11302-006-9003-5","article-title":"The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance","volume":"2","author":"Robson","year":"2006","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.biopha.2023.115184_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11302-006-9000-8","article-title":"Ecto-5\u2019-nucleotidase: structure function relationships","volume":"2","author":"Str\u00e4ter","year":"2006","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.biopha.2023.115184_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092223","article-title":"Thrombo-inflammation: a focus on NTPDase1\/CD39","volume":"10","author":"Morello","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2023.115184_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.mam.2012.05.007","article-title":"The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29","volume":"34","author":"Young","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1042\/BST20160038","article-title":"The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey","volume":"44","author":"Young","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.biopha.2023.115184_bib17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/pr.112.006361","article-title":"Adenosine Kinase: exploitation for therapeutic gain","volume":"65","author":"Boison","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2023.115184_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tips.2016.02.006","article-title":"Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects","volume":"37","author":"Borea","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib19","doi-asserted-by":"crossref","unstructured":"A. Newby, Y. Worku, P. Meghji, M. Nakazawa, A. Skladanowski, Adenosine: A Retaliatory Metabolite or Not?, Https:\/\/Doi.Org\/10.1152\/Physiologyonline.1990.5.2.67. 5 (1990) 67\u201370. https:\/\/doi.org\/10.1152\/PHYSIOLOGYONLINE.1990.5.2.67.","DOI":"10.1152\/physiologyonline.1990.5.2.67"},{"key":"10.1016\/j.biopha.2023.115184_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2023.115184_bib21","doi-asserted-by":"crossref","unstructured":"M. Gaudry, D. Vairo, M. Marlinge, M. Gaubert, C. Guiol, G. Mottola, V. Gariboldi, P. Deharo, S. Sadrin, J.M. Maixent, E. Fenouillet, J. Ruf, R. Guieu, F. Paganelli, Molecular Sciences Adenosine and Its Receptors: An Expected Tool for the Diagnosis and Treatment of Coronary Artery and Ischemic Heart Diseases, (n.d.). https:\/\/doi.org\/10.3390\/ijms21155321.","DOI":"10.3390\/ijms21155321"},{"key":"10.1016\/j.biopha.2023.115184_bib22","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/ijms15022024","article-title":"Adenosine receptors: expression, function and regulation","volume":"15","author":"Sheth","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib23","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.2174\/1381612825666190716145206","article-title":"Role and function of adenosine and its receptors in inflammation, neuroinflammation, IBS, autoimmune inflammatory disorders, rheumatoid arthritis and psoriasis","volume":"25","author":"Shakya","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2023.115184_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/j.1748-1716.1981.tb06819.x","article-title":"Role of adenosine in adipose tissue circulation","author":"Sollevi","year":"1981","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.biopha.2023.115184_bib25","first-page":"243","article-title":"Adenosine and tubuloglomerular feedback","volume":"15","author":"Osswald","year":"1997","journal-title":"Blood Purif."},{"key":"10.1016\/j.biopha.2023.115184_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2016.04.001","article-title":"Immunosuppressive activities of adenosine in cancer","volume":"29","author":"Allard","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051366","article-title":"Adenosine and the cardiovascular system: the good and the bad","volume":"9","author":"Guieu","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-3-540-89615-9_6","article-title":"Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology","volume":"193","author":"Mustafa","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib29","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/0002-8703(92)90525-Z","article-title":"Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome","volume":"123","author":"Wesley","year":"1992","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2023.115184_bib30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0735-1097(10)80078-6","article-title":"Coronary flow reserve as a physiologic measure of stenosis severity","volume":"15","author":"Gould","year":"1990","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib31","first-page":"317","article-title":"Adenosine stress thallium-201 myocardial perfusion imaging for detecting coronary artery disease at an early stage","volume":"21","author":"Chen","year":"2013","journal-title":"J. Xray Sci. Technol."},{"key":"10.1016\/j.biopha.2023.115184_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000213","article-title":"Signaling by adenosine receptors\u2014Homeostatic or allostatic control","volume":"17","author":"Cunha","year":"2019","journal-title":"PLoS Biol."},{"issue":"2018","key":"10.1016\/j.biopha.2023.115184_bib33","article-title":"Inhibition of IL-17 and IL-23 in human keratinocytes by the A3 adenosine receptor agonist piclidenoson","author":"Cohen","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.biopha.2023.115184_bib34","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.3390\/molecules27123680","article-title":"Drugs targeting the A3 adenosine receptor: human clinical study data","volume":"27","author":"Ciancetta","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.115184_bib35","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1517\/13543784.16.10.1601","article-title":"The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis","volume":"16","author":"Bar-Yehuda","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2023.115184_bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/DDDT.S195294","article-title":"Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy","volume":"13","author":"Cohen","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2023.115184_bib37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1254\/jphs.13250FP","article-title":"The adenosine A2A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets","volume":"124","author":"Uchida","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib38","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1471-4159.1991.tb08257.x","article-title":"Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study","volume":"57","author":"Schiffmann","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2023.115184_bib39","doi-asserted-by":"crossref","unstructured":"A.A. Berger, A. Winnick, A. Welschmeyer, A. Kaneb, K. Berardino, E.M. Cornett, A.D. Kaye, O. Viswanath, I. Urits, Istradefylline to Treat Patients with Parkinson\u2019s Disease Experiencing \u201cOff\u201d Episodes: A Comprehensive Review, (n.d.). https:\/\/doi.org\/10.3390\/neurolint12030017.","DOI":"10.3390\/neurolint12030017"},{"key":"10.1016\/j.biopha.2023.115184_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0014-2999(94)90689-0","article-title":"Modulation of striatal adenosine A1 and A2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats","volume":"257","author":"Popoli","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib41","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","article-title":"Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson\u2019s disease","volume":"21","author":"Chen","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2023.115184_bib42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1517\/13543784.14.6.729","article-title":"Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson\u2019s disease","volume":"14","author":"Jenner","year":"2005","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2023.115184_bib43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40263-014-0161-7","article-title":"Adenosine A2A receptor antagonists in Parkinson\u2019s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued","volume":"28","author":"Pinna","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopha.2023.115184_bib44","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1523\/JNEUROSCI.23-34-10982.2003","article-title":"Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively","volume":"23","author":"Alfinito","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2023.115184_bib45","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.neuropharm.2004.11.009","article-title":"KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse","volume":"48","author":"Pierri","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2023.115184_bib46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neulet.2018.03.040","article-title":"Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson\u2019s disease","volume":"675","author":"Kumari","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2023.115184_bib47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0b013e318263570d","article-title":"Caffeine for treatment of Parkinson disease: a randomized controlled trial","volume":"79","author":"Postuma","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2023.115184_bib48","first-page":"1","article-title":"The effect of istradefylline for Parkinson\u2019s disease: a meta-analysis","volume":"7","author":"Sako","year":"2017","journal-title":"Sci. Rep. 2017 71"},{"key":"10.1016\/j.biopha.2023.115184_bib49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1474-4422(11)70012-6","article-title":"Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial","volume":"10","author":"Hauser","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2023.115184_bib50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S1474-4422(14)70148-6","article-title":"Tozadenant (SYN115) in patients with Parkinson\u2019s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial","volume":"13","author":"Hauser","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2023.115184_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27123680","article-title":"Drugs targeting the A3 adenosine receptor: human clinical study data","volume":"27","author":"Fishman","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.115184_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073764","article-title":"Macrophage-derived adenosine deaminase 2 correlates with m2 macrophage phenotype in triple negative breast cancer","volume":"22","author":"Kutryb-Zajac","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib53","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.2174\/1381612825666190716102037","article-title":"Adenosine receptors as novel targets for the treatment of various cancers","volume":"25","author":"Gorain","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2023.115184_bib54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/978-3-540-89615-9_14","article-title":"Adenosine receptors and cancer","volume":"193","author":"Fishman","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib55","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","article-title":"Impact of the selective A2AR and A2BR dual antagonist AB928\/etrumadenant on CAR T cell function","volume":"127","author":"Seifert","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2023.115184_bib56","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10637-018-0706-6","article-title":"Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers","volume":"37","author":"Seitz","year":"2019","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.biopha.2023.115184_bib57","doi-asserted-by":"crossref","first-page":"v493","DOI":"10.1093\/annonc\/mdz253.032","article-title":"Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies","volume":"30","author":"Powderly","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.115184_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.24352","article-title":"Adenosine, adenosine receptors and their role in glucose homeostasis and lipid metabolism.","author":"Koupenova","year":"2013","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2023.115184_bib59","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s11154-021-09668-8","article-title":"Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes","volume":"22","author":"Sanni","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.biopha.2023.115184_bib60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.addr.2019.02.005","article-title":"Adenosine and lipids: a forced marriage or a love match","volume":"152","author":"Rouquette","year":"2019","journal-title":"Adv. Drug Deliv. Rev. 151\u2013"},{"key":"10.1016\/j.biopha.2023.115184_bib61","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF02255947","article-title":"Modulation of catecholamine release by endogenous adenosine in the rat adrenal medulla","volume":"8","author":"Tseng","year":"2001","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib62","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.3390\/ijms21155321","article-title":"Adenosine and its receptors: an expected tool for the diagnosis and treatment of coronary artery and ischemic heart diseases","volume":"21","author":"Gaudry","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228710","article-title":"Targeting adenosine receptors: a potential pharmacological avenue for acute and chronic pain","author":"Vincenzi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2018.00482","article-title":"Adenosine actions on oligodendroglia and myelination in autism spectrum disorder","author":"Shen","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.biopha.2023.115184_bib65","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-89615-9_11","article-title":"Adenosine receptors and asthma","author":"Wilson","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib66","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-89615-9_15","article-title":"Adenosine receptors and the kidney","author":"Vallon","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib67","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/joa3.12453","article-title":"Adenosine\u2014a drug with myriad utility in the diagnosis and treatment of arrhythmias","volume":"37","author":"Gupta","year":"2021","journal-title":"J. Arrhythmia"},{"key":"10.1016\/j.biopha.2023.115184_bib68","doi-asserted-by":"crossref","unstructured":"M. Williams, Purine Receptors in Mammalian Tissues: Pharmacology and Functional Significance, Https:\/\/Doi.Org\/10.1146\/Annurev.Pa.27.040187.001531. 27 (2003) 315\u2013345. https:\/\/doi.org\/10.1146\/ANNUREV.PA.27.040187.001531.","DOI":"10.1146\/annurev.pa.27.040187.001531"},{"key":"10.1016\/j.biopha.2023.115184_bib69","first-page":"1854","article-title":"Adenosine","volume":"82","author":"Pantely","year":"1990","journal-title":"Renewed Interest Old. Drug, Circ."},{"key":"10.1016\/j.biopha.2023.115184_bib70","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/CIRCULATIONAHA.117.028414","article-title":"Real-life fractional flow reserve","volume":"135","author":"De Bruyne","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115184_bib71","first-page":"317","article-title":"Adenosine stress thallium-201 myocardial perfusion imaging for detecting coronary artery disease at an early stage","volume":"21","author":"Chen","year":"2013","journal-title":"J. Xray Sci. Technol."},{"key":"10.1016\/j.biopha.2023.115184_bib72","doi-asserted-by":"crossref","unstructured":"P. Talik, J. Krzek, R.J. Ekiert, Analytical Techniques Used for Determination of Methylxanthines and their Analogues\u2014Recent Advances, Http:\/\/Dx.Doi.Org\/10.1080\/15422119.2011.569047. 41 (2011) 1\u201361. https:\/\/doi.org\/10.1080\/15422119.2011.569047.","DOI":"10.1080\/15422119.2011.569047"},{"key":"10.1016\/j.biopha.2023.115184_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/foods6120109","article-title":"Methylxanthine content in commonly consumed foods in spain and determination of its intake during consumption","volume":"6","author":"Sanchez","year":"2017","journal-title":"Foods"},{"key":"10.1016\/j.biopha.2023.115184_bib74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.0954-6820.1985.tb01650.x","article-title":"On the mechanism of action of theophylline and caffeine","volume":"217","author":"Fredholm","year":"1985","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.biopha.2023.115184_bib75","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-3-642-13443-2_16","article-title":"The cardiovascular effects of methylxanthines","volume":"200","author":"Riksen","year":"2011","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.biopha.2023.115184_bib76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-642-13443-2_6","article-title":"Xanthines as adenosine receptor antagonists","volume":"200","author":"M\u00fcller","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib77","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1038\/sj.bjp.0706495","article-title":"Phosphodiesterase inhibitors","volume":"147","author":"Boswell-Smith","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib78","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00001756-200103050-00013","article-title":"Inhibitory effect of theophylline on recombinant GABAA receptor","volume":"12","author":"Sugimoto","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.biopha.2023.115184_bib79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1242\/jeb.107.1.73","article-title":"Influence of some common methylxanthines on contractile responses and calcium mobilization of ileal, vas deferens and bladder smooth muscle","volume":"107","author":"Huddart","year":"1983","journal-title":"J. Exp. Biol."},{"key":"10.1016\/j.biopha.2023.115184_bib80","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/rccm.201302-0388PP","article-title":"Theophylline","volume":"188","author":"Barnes","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2023.115184_bib81","first-page":"1","article-title":"Methylxanthines","author":"Geib","year":"2016","journal-title":"Crit. Care Toxicol."},{"key":"10.1016\/j.biopha.2023.115184_bib82","unstructured":"M. Lazarus H.-Y. Shen Y. Cherasse W.-M. Qu Z.-L. Huang C.E. Bass R. Winsky-Sommerer K. Semba B.B. Fredholm D. Boison O. Hayaishi Y. Urade J.-F. Chen. Behav. \/Syst. \/Cogn. Arousa Eff. Caffeine Depends Aden A 2A Recept. Shell Nucl. Accumbens 2011 doi:\u00a010.1523\/JNEUROSCI.6730-10.2011."},{"key":"10.1016\/j.biopha.2023.115184_bib83","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3389\/fphar.2021.681842","article-title":"Caffeine for the pharmacological treatment of apnea of prematurity in the NICU: dose selection conundrum, therapeutic drug monitoring and genetic factors","volume":"12","author":"Long","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib84","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(67)91890-9","article-title":"Aminophylline in bronchial asthma","volume":"290","author":"Rees","year":"1967","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.115184_bib85","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pedneo.2016.10.003","article-title":"Caffeine citrate \u2013 Is it a silver bullet in neonatology?","volume":"58","author":"Shrestha","year":"2017","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.biopha.2023.115184_bib86","first-page":"961","article-title":"Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors","volume":"41","author":"Froestl","year":"2014","journal-title":"Update 2014, J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2023.115184_bib87","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11302-008-9100-8","article-title":"Adenosine A2A receptors in Parkinson\u2019s disease treatment","volume":"4","author":"Cie\u015blak","year":"2008","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.biopha.2023.115184_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2020.10.023","article-title":"Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems","author":"Pinna","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.biopha.2023.115184_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2020.10.024","article-title":"Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson\u2019s disease?","author":"Chen","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.biopha.2023.115184_bib90","unstructured":"R.B. Postuma, J. Anang, A. Pelletier, L. Joseph, M. Moscovich, D. Grimes, S. Furtado, R.P. Munhoz, S. Appel-Cresswell, A. Moro, A. Borys, D. Hobson, A.E. Lang, Caffeine symptomatic Treat. Park. Dis. (Caf\u00e9-PD) A Random Trial 2017."},{"key":"10.1016\/j.biopha.2023.115184_bib91","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WNF.0b013e3181d137d2","article-title":"An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers","volume":"33","author":"Brooks","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib92","doi-asserted-by":"crossref","unstructured":"A. Mori, How do adenosine A2A receptors regulate motor function? Park. Relat. Disord. 80 1 2020 S13 S20 doi:\u00a010.1016\/J.PARKRELDIS.2020.09.025.","DOI":"10.1016\/j.parkreldis.2020.09.025"},{"key":"10.1016\/j.biopha.2023.115184_bib93","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/neurolint12030017","article-title":"Istradefylline to treat patients with Parkinson\u2019s disease experiencing \u201coff\u201d episodes: a comprehensive review","volume":"12","author":"Berger","year":"2020","journal-title":"Neurol. Int."},{"key":"10.1016\/j.biopha.2023.115184_bib94","doi-asserted-by":"crossref","first-page":"222","DOI":"10.20517\/2347-8659.2020.58","article-title":"A review on Parkinson\u2019s disease treatment","volume":"8","author":"Lee","year":"2021","journal-title":"Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.biopha.2023.115184_bib95","article-title":"Initial drug treatment in Parkinson\u2019s disease","volume":"351","author":"Muzerengi","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2023.115184_bib96","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2023.115184_bib97","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.biopha.2023.115184_bib98","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12350-011-9474-9","article-title":"Selective adenosine agonists and myocardial perfusion imaging","volume":"19","author":"Zoghbi","year":"2012","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib99","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2009.04.089","article-title":"Regadenoson: a new myocardial stress agent","volume":"54","author":"Al Jaroudi","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib100","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.nuclcard.2007.02.016","article-title":"Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans","volume":"14","author":"Lieu","year":"2007","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib101","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial","volume":"14","author":"Iskandrian","year":"2007","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1465-9921-10-58","article-title":"Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation","volume":"10","author":"Sharma","year":"2009","journal-title":"Respir. Res."},{"key":"10.1016\/j.biopha.2023.115184_bib103","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.athoracsur.2004.09.038","article-title":"Adenosine A2A receptor agonist improves cardiac dysfunction from pulmonary ischemia-reperfusion injury","volume":"79","author":"Reece","year":"2005","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.biopha.2023.115184_bib104","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neulet.2010.06.025","article-title":"Roles of adenosine receptor subtypes on the antinociceptive effect of sildenafil in rat spinal cord","volume":"480","author":"Lee","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2023.115184_bib105","doi-asserted-by":"crossref","first-page":"S846","DOI":"10.1016\/j.annonc.2020.08.1623","article-title":"1309P ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC)","volume":"31","author":"Spira","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.115184_bib106","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11302-012-9350-3","article-title":"A2B adenosine receptor blockade inhibits growth of prostate cancer cells","volume":"9","author":"Wei","year":"2013","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.biopha.2023.115184_bib107","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.3390\/ijms20205139","article-title":"A2B adenosine receptor and cancer","volume":"20","author":"Gao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib108","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cellimm.2009.03.020","article-title":"The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn\u2019s disease","volume":"258","author":"Ochaion","year":"2009","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.biopha.2023.115184_bib109","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.07.002","article-title":"Adenosine receptors as potential targets in melanoma","volume":"76","author":"Montinaro","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2023.115184_bib110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/DDDT.S195294","article-title":"Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy","volume":"Volume 13","author":"Cohen","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2023.115184_bib111","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s10067-016-3202-4","article-title":"The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis","volume":"35","author":"Fishman","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.biopha.2023.115184_bib112","first-page":"727","article-title":"Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101","volume":"28","author":"Bar-Yehuda","year":"2011","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib113","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/art.24817","article-title":"Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment","volume":"60","author":"Bar-Yehuda","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2023.115184_bib114","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/MIB.0000000000000047","article-title":"Potential for developing purinergic drugs for gastrointestinal diseases","volume":"20","author":"Ochoa-Cortes","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.biopha.2023.115184_bib115","first-page":"287","article-title":"The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-\u03baB signal transduction pathways","volume":"33","author":"Bar-Yehuda","year":"2008","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2023.115184_bib116","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/jcp.22593","article-title":"CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver","volume":"226","author":"Cohen","year":"2011","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2023.115184_bib117","first-page":"1245","article-title":"A3 adenosine receptor agonist potentiates natural killer cell activity","volume":"23","author":"Harish","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2023.115184_bib118","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.3892\/mmr.2016.5746","article-title":"A3 adenosine receptor agonist, CF102, protects against hepatic ischemia\/reperfusion injury following partial hepatectomy","volume":"14","author":"Ohana","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2023.115184_bib119","first-page":"2256","article-title":"The A3 adenosine receptor agonist, namodenoson, ameliorates non\u2011alcoholic steatohepatitis in mice","volume":"44","author":"Fishman","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib120","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40273-013-0088-8","article-title":"Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations","volume":"31","author":"Weintraub","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.biopha.2023.115184_bib121","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40256-018-0291-2","article-title":"Oral antiplatelet therapy for secondary prevention of acute coronary syndrome","volume":"18","author":"Berger","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.biopha.2023.115184_bib122","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/asheducation-2009.1.267","article-title":"Antiplatelet agents","author":"Varon","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"10.1016\/j.biopha.2023.115184_bib123","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2125.1998.t01-1-00677.x","article-title":"Do we still need dipyridamole?","volume":"45","author":"Gibbs","year":"1998","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.115184_bib124","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.107.160226","article-title":"Translational therapeutics of dipyridamole","volume":"28","author":"Kim","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2023.115184_bib125","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1074\/jbc.275.12.8375","volume":"275","author":"Ward","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.115184_bib126","doi-asserted-by":"crossref","first-page":"R289","DOI":"10.1186\/cc10576","article-title":"Dipyridamole augments the antiinflammatory response during human endotoxemia","volume":"15","author":"Ramakers","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.biopha.2023.115184_bib127","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.STR.0000056527.34434.59","article-title":"Dipyridamole enhances NO\/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: In vitro and in vivo\/ex vivo studies","volume":"34","author":"Aktas","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.biopha.2023.115184_bib128","doi-asserted-by":"crossref","unstructured":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial Lancet 367 2006 1665 1673 doi:\u00a010.1016\/S0140-6736(06)68734-5.","DOI":"10.1016\/S0140-6736(06)68734-5"},{"key":"10.1016\/j.biopha.2023.115184_bib129","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0404.1999.tb00658.x","article-title":"Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group","volume":"99","author":"Sivenius","year":"1999","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.biopha.2023.115184_bib130","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib131","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0022-5223(95)70243-1","article-title":"Effects of dipyridamole in combination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves. A meta-analysis of the randomized trials","volume":"110","author":"Pouleur","year":"1995","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.biopha.2023.115184_bib132","doi-asserted-by":"crossref","unstructured":"K.F. Aliter, R.A. Al-Horani, in COVID-19 patients Curr. Pharm. Des. 27 2021 866 875 doi:\u00a010.2174\/1381612826666201001125604.","DOI":"10.2174\/1381612826666201001125604"},{"key":"10.1016\/j.biopha.2023.115184_bib133","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/infdis\/jiz344","article-title":"A randomized, placebo-controlled, pilot clinical trial of dipyridamole to decrease human immunodeficiency virus\u2013associated chronic inflammation","volume":"221","author":"Macatangay","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.115184_bib134","unstructured":"Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19 - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04424901?term=04424901&draw=2&rank=1 (accessed March 1, 2023)."},{"key":"10.1016\/j.biopha.2023.115184_bib135","unstructured":"DICER) in COVID-19 - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04391179?term=04391179&draw=2&rank=1 (accessed March 1, 2023)."},{"key":"10.1016\/j.biopha.2023.115184_bib136","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000222782","article-title":"Dipyridamole-associated headache in stroke patients \u2013 interindividual differences","volume":"62","author":"L\u00f6kk","year":"2009","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.biopha.2023.115184_bib137","first-page":"21","article-title":"Adverse reactions to dipyridamole in patients undergoing stress\/rest cardiac perfusion testing","volume":"30","author":"Meyers","year":"2002","journal-title":"J. Nucl. Med. Technol."},{"key":"10.1016\/j.biopha.2023.115184_bib138","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12350-015-0387-x","article-title":"ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers","volume":"23","author":"Henzlova","year":"2016","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib139","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0735-1097(91)90604-8","article-title":"Comparison of coronary vasodilation with intravenous dipyridamole and adenosine","volume":"18","author":"Rossen","year":"1991","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/157489007782418991","article-title":"Cilostazol: a new drug in the treatment intermittent claudication","volume":"2","author":"Kumar","year":"2007","journal-title":"Recent Pat. Cardiovasc. Drug Discov."},{"key":"10.1016\/j.biopha.2023.115184_bib141","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib142","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/01.RES.0000258451.44949.d7","article-title":"Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart","volume":"100","author":"Yan","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2023.115184_bib143","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1527-3466.2001.tb00076.x","article-title":"Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake","volume":"19","author":"Liu","year":"2001","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.biopha.2023.115184_bib144","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2459\/JCM.0b013e3283439746","article-title":"Effects of cilostazol in the heart","volume":"12","author":"Kanlop","year":"2011","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib145","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1097\/00006534-199712000-00019","article-title":"The effect of ischemic preconditioning on the recovery of skeletal muscle following tourniquet ischemia","volume":"100","author":"Whetzel","year":"1997","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.biopha.2023.115184_bib146","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10557-005-6896-0","article-title":"Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation","volume":"19","author":"Li","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.biopha.2023.115184_bib147","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005344-200408000-00017","article-title":"Cilostazol and dipyridamole synergistically inhibit human platelet aggregation","volume":"44","author":"Liu","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib148","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosissup.2005.09.005","article-title":"Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination","volume":"6","author":"Comerota","year":"2005","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.biopha.2023.115184_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107336","article-title":"Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target","volume":"92","author":"Motta","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib150","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","article-title":"Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist","volume":"27","author":"Husted","year":"2009","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.biopha.2023.115184_bib151","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2125.2011.03999.x","article-title":"Anti-platelet therapy: ADP receptor antagonists","volume":"72","author":"Wijeyeratne","year":"2011","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.115184_bib152","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/bph.13429","article-title":"Effects of P2Y12 receptor antagonists beyond platelet inhibition \u2013 comparison of ticagrelor with thienopyridines","volume":"173","author":"Nylander","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib153","article-title":"Pleiotropic actions of ticagrelor versus clopidogrel \u2013 Do molecular differences translate into superior clinical efficacy after myocardial infarction?","volume":"27","author":"Fender","year":"2020","journal-title":"Int. J. Cardiol. Hear. Vasc."},{"key":"10.1016\/j.biopha.2023.115184_bib154","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115184_bib155","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib156","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacc.2012.11.032","article-title":"Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans","volume":"61","author":"Wittfeldt","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib157","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/ATVBAHA.112.300484","article-title":"Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure","volume":"33","author":"Nicholson","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2023.115184_bib158","doi-asserted-by":"crossref","unstructured":"D. Garcia-Dorado, on behalf of PROMISE, I. Otaegui, on behalf of PROMISE, J.F. Rodriguez Palomares, on behalf of PROMISE, A. Evangelista, on behalf of PROMISE, V. Pineda, on behalf of PROMISE, R. Ruiz Salmeron, on behalf of PROMISE, F. Gimeno, on behalf of PROMISE, F. Fernandez Aviles, on behalf of PROMISE, A. San Roman, on behalf of PROMISE, B. Garcia Del Blanco, on behalf of PROMISE, Primary results of the PROMISE trial: myocardial protection with intracoronary adenosine given before reperfusion in patients with STEMI, Eur. Heart J. 34 (2013) 3736\u20133736. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHT309.3736.","DOI":"10.1093\/eurheartj\/eht309.3736"},{"key":"10.1016\/j.biopha.2023.115184_bib159","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/0897190016680978","article-title":"Successful reversal of bradycardia and dyspnea with aminophylline after ticagrelor load","volume":"31","author":"Minner","year":"2018","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.biopha.2023.115184_bib160","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1161\/01.STR.0000179044.37760.9d","article-title":"Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole","volume":"36","author":"Gamboa","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.biopha.2023.115184_bib161","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jth.12360","article-title":"Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism","volume":"11","author":"Nylander","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2023.115184_bib162","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1016\/j.bmcl.2007.07.057","article-title":"From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis","volume":"17","author":"Springthorpe","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2023.115184_bib163","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1074248411410883","article-title":"Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model","volume":"17","author":"Van Giezen","year":"2012","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2023.115184_bib164","doi-asserted-by":"crossref","first-page":"A22","DOI":"10.1016\/S0735-1097(14)60022-X","article-title":"Ticagrelor, but not clopidogrel, protects the heart and limits myocardial infarct size","volume":"63","author":"Birnbaum","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib165","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","article-title":"Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome","volume":"63","author":"Bonello","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib166","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCULATIONAHA.118.034489","article-title":"Adenosine and ticagrelor plasma levels in patients with and without ticagrelor- related dyspnea","volume":"138","author":"Ortega-Paz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115184_bib167","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012228","article-title":"Evaluation of plasma adenosine as a marker of cardiovascular risk: analytical and biological considerations.","volume":"8","author":"Simard","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2023.115184_bib168","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/cts.12886","article-title":"Performance of plasma adenosine as a biomarker for predicting cardiovascular risk","volume":"14","author":"Simard","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib169","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1515\/BC.2006.042","article-title":"Human plasma adenosine deaminase 2 is secreted by activated monocytes","volume":"387","author":"Iwaki-Egawa","year":"2006","journal-title":"Biol. Chem."},{"key":"10.1016\/j.biopha.2023.115184_bib170","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1182\/blood-2014-05-572024","article-title":"Hemolysis is a primary ATP-release mechanism in human erythrocytes","volume":"124","author":"Sikora","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115184_bib171","doi-asserted-by":"crossref","first-page":"H90","DOI":"10.1152\/ajpheart.00570.2020","article-title":"Ticagrelor: a cardiometabolic drug targeting erythrocyte-mediated purinergic signaling?","volume":"320","author":"Wernly","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.biopha.2023.115184_bib172","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbrc.2012.01.093","article-title":"Ticagrelor induces adenosine triphosphate release from human red blood cells","volume":"418","author":"Ohman","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2023.115184_bib173","doi-asserted-by":"crossref","unstructured":"M. Cattaneo, R. Schulz, S. Nylander, Phd Milan, Adenosine-Mediated Effects of Ticagrelor Evidence and Potential Clinical Relevance, (n.d.). https:\/\/doi.org\/10.1016\/j.jacc.2014.03.031.","DOI":"10.1016\/j.jacc.2014.03.031"},{"key":"10.1016\/j.biopha.2023.115184_bib174","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/TCRM.S152369","article-title":"Ticagrelor \u2013 toward more efficient platelet inhibition and beyond","volume":"14","author":"Kubisa","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.biopha.2023.115184_bib175","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF01534273","article-title":"Nonsteroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: adenosine dependent and independent mechanisms","volume":"18","author":"Cronstein","year":"1994","journal-title":"Inflammation"},{"key":"10.1016\/j.biopha.2023.115184_bib176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(02)01828-9","article-title":"Anti-inflammatory effects of aspirin and sodium salicylate","volume":"447","author":"Amann","year":"2002","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2023.115184_bib177","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1073\/pnas.96.11.6377","article-title":"Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB","volume":"96","author":"Cronstein","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.115184_bib178","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.156.5.1937","article-title":"The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites","author":"Gadangi","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2023.115184_bib179","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.22643","article-title":"The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5\u2032-nucleotidase: Findings in a study of ecto-5\u2032-nucleotidase gene\u2013deficient mice","volume":"56","author":"Montesinos","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2023.115184_bib180","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000493390","article-title":"Rheumatoid arthritis: a brief overview of the treatment","volume":"27","author":"Bullock","year":"2019","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.biopha.2023.115184_bib181","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0006-2952(00)00578-5","article-title":"Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo","volume":"61","author":"Eli","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib182","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejphar.2006.01.008","article-title":"Nonsteroidal anti-inflammatory drugs inhibit the growth of C6 and U138-MG glioma cell lines","volume":"532","author":"Bernardi","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib183","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2007.04.058","article-title":"Indomethacin stimulates activity and expression of ecto-5\u2019-nucleotidase\/CD73 in glioma cell lines","volume":"569","author":"Bernardi","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib184","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM199305063281805","article-title":"Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis","volume":"328","author":"Giardiello","year":"1993","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib185","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1916063","article-title":"Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis","volume":"383","author":"Burke","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib186","first-page":"255","article-title":"Effect of nimesulide on the indomethacin- and ibuprofen-induced ulcer in rat gastric tissue","volume":"54","author":"S\u00fcleyman","year":"2002","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib187","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1185\/030079906X104849","article-title":"Nimesulide -- a multifactorial approach to inflammation and pain: scientific and clinical consensus","volume":"22","author":"Rainsford","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.biopha.2023.115184_bib188","first-page":"105","article-title":"The relatively selective cyclooxygenase-2 inhibitor nimesulide: What\u2019s going on?, Eur","volume":"848","author":"Caiazzo","year":"2019","journal-title":"J. Pharm."},{"key":"10.1016\/j.biopha.2023.115184_bib189","first-page":"992","article-title":"Inhibition of neutrophil function in vitro by nimesulide","volume":"43","author":"Capecchi","year":"1993","journal-title":"Prelim. Evid. Aden -Mediat. Mech., Arzneim."},{"key":"10.1016\/j.biopha.2023.115184_bib190","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejphar.2010.07.006","article-title":"Nimesulide improves the disease modifying anti-rheumatic profile of methotrexate in mice with collagen-induced arthritis","volume":"644","author":"Al-Abd","year":"2010","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2023.115184_bib191","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bcp.2016.05.006","article-title":"Adenosine signalling mediates the anti-inflammatory effects of the COX-2 inhibitor nimesulide","volume":"112","author":"Caiazzo","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib192","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/phrs.1998.0417","article-title":"Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide","volume":"39","author":"Gupta","year":"1999","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2023.115184_bib193","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.phrs.2008.03.003","article-title":"Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences","volume":"57","author":"Candelario-Jalil","year":"2008","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2023.115184_bib194","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1078-0432.CCR-0902-03","article-title":"Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma","volume":"10","author":"Shaik","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.115184_bib195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2008.10.028","article-title":"Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms","volume":"276","author":"Liang","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2023.115184_bib196","first-page":"370","article-title":"Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN","volume":"16","author":"Chu","year":"2018","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.biopha.2023.115184_bib197","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1538\/expanim.15-0122","article-title":"Effects of nimesulide on the small intestine mucositis induced bymethotrexate in rats","volume":"65","author":"Arslan","year":"2016","journal-title":"Exp. Anim."},{"key":"10.1016\/j.biopha.2023.115184_bib198","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3748\/wjg.v12.i4.568","article-title":"Attenuation of gastric mucosal inflammation induced by aspirin through activation of A2A adenosine receptor in rats","volume":"12","author":"Odashima","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.115184_bib199","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00535-009-0028-8","article-title":"Attenuation of gastric mucosal inflammation induced by indomethacin through activation of the A2A adenosine receptor in rats","volume":"44","author":"Koizumi","year":"2009","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.115184_bib200","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00273","article-title":"Adenosine receptor stimulation by polydeoxyribonucleotide improves tissue repair and symptomology in experimental colitis","volume":"7","author":"Pallio","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib201","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-022-01308-5","article-title":"Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors","volume":"41","author":"Pant","year":"2023","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.biopha.2023.115184_bib202","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0733-8635(05)70233-3","article-title":"Antimetabolites and cytotoxic drugs","volume":"19","author":"Silvis","year":"2001","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.biopha.2023.115184_bib203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/B978-0-444-52824-7.00002-0","article-title":"Antimetabolites","author":"Avenda\u00f1o","year":"2008","journal-title":"Med. Chem. Anticancer Drugs"},{"key":"10.1016\/j.biopha.2023.115184_bib204","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.celrep.2019.07.099","article-title":"Ribavirin Induces Polyamine Depletion via Nucleotide Depletion to Limit Virus Replication","volume":"28","author":"Tate","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2023.115184_bib205","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1021\/acschembio.6b00357","article-title":"Structure-based screening of uncharted chemical space for atypical adenosine receptor agonists","volume":"11","author":"Rodr\u00edguez","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.biopha.2023.115184_bib206","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1196\/annals.1342.048","article-title":"Different effects of adenosine A1 agonist ribavirin on amphetamine-induced total locomotor and stereotypic activities in rats","volume":"1048","author":"Jana\u0107","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib207","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00221-005-2311-0","article-title":"The time-course of ribavirin-provoked changes of basal and AMPH-induced motor activities in rats","volume":"165","author":"Jana\u0107","year":"2005","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.biopha.2023.115184_bib208","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1365-2036.2011.04867.x","article-title":"Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C","volume":"34","author":"De Knegt","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2023.115184_bib209","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.nut.2011.08.010","article-title":"Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment","volume":"28","author":"Fioravante","year":"2012","journal-title":"Nutrition"},{"key":"10.1016\/j.biopha.2023.115184_bib210","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s13365-014-0265-3","article-title":"Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment","volume":"20","author":"Cattie","year":"2014","journal-title":"J. Neurovirol"},{"key":"10.1016\/j.biopha.2023.115184_bib211","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jhet.5570110438","article-title":"A novel adenosine and ara-a deaminase inhibitor, (R)-3-(2-deoxy-\u03b2-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5 -d] [1,3]diazepin-8-ol","volume":"11","author":"Woo","year":"1974","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.biopha.2023.115184_bib212","first-page":"74","article-title":"Comparison and possible homology of isozymes of adenosine deaminase in Aves and humans","volume":"26","author":"Ratech","year":"1981","journal-title":"Enzyme"},{"key":"10.1016\/j.biopha.2023.115184_bib213","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.3390\/molecules25204652","article-title":"Therapeutic perspectives of adenosine deaminase inhibition in cardiovascular diseases","volume":"25","author":"Kutryb-Zajac","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.115184_bib214","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115184_bib215","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1158\/1078-0432.CCR-15-0340","article-title":"High-dose sirolimus and immune-selective pentostatin plus cyclophosphamide conditioning yields stable mixed chimerism and insufficient graft-versus-tumor responses","volume":"21","author":"Mossoba","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.115184_bib216","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.5139.5139","article-title":"Weekly combination chemotherapy with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for newly diagnosed patients with advanced cardiac disease due to systemic AL amyloidosis","volume":"118","author":"Cossor","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115184_bib217","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2015.132035","article-title":"A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients","volume":"100","author":"Tedeschi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2023.115184_bib218","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000500164","article-title":"Pentostatin, cyclophosphamide, and rituximab followed by alemtuzumab for relapsed or refractory chronic lymphocytic leukemia: a phase 2 trial of the ECOG-acrin cancer research group (E2903)","volume":"142","author":"Kempin","year":"2019","journal-title":"Acta Haematol."},{"key":"10.1016\/j.biopha.2023.115184_bib219","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3816\/CLM.2005.n.039","article-title":"Pentostatin\/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom\u2019s macroglobulinemia\/lymphoplasmacytic lymphoma","volume":"6","author":"Hensel","year":"2005","journal-title":"Clin. Lymphoma Myeloma"},{"key":"10.1016\/j.biopha.2023.115184_bib220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/10428194.2014.911869","article-title":"Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"56","author":"Herth","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2023.115184_bib221","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/biom12030418","article-title":"Adenosine-metabolizing enzymes, adenosine kinase and adenosine deaminase, in cancer","volume":"12","author":"Zhulai","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2023.115184_bib222","doi-asserted-by":"crossref","unstructured":"B.J. Kane, J.G. Kuhn, M.K. Roush, Pentostatin: An Adenosine Deaminase Inhibitor for the Treatment of Hairy Cell Leukemia, Http:\/\/Dx.Doi.Org\/10.1177\/106002809202600718. 26 (1992) 939\u2013947. https:\/\/doi.org\/10.1177\/106002809202600718.","DOI":"10.1177\/106002809202600718"},{"key":"10.1016\/j.biopha.2023.115184_bib223","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0301-0082(97)00013-0","article-title":"Cell surface adenosine deaminase: much more than an ectoenzyme","volume":"52","author":"Franco","year":"1997","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2023.115184_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.yjmcc.2019.01.004","article-title":"Inhibition of LPS-stimulated ecto-adenosine deaminase attenuates endothelial cell activation","volume":"128","author":"Kutryb-Zajac","year":"2019","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib225","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428194.2011.570394","article-title":"Mechanism of action of pentostatin and cladribine in hairy cell leukemia","volume":"52","author":"Johnston","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2023.115184_bib226","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537","article-title":"Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria","volume":"96","author":"Genini","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115184_bib227","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.dnarep.2014.09.004","article-title":"ARTD1 (PARP1) activation and NAD+ in DNA repair and cell death","volume":"0","author":"Fouquerel","year":"2014","journal-title":"DNA Repair"},{"key":"10.1016\/j.biopha.2023.115184_bib228","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1078-0432.CCR-0755-03","article-title":"CD26 expression correlates with a reduced sensitivity to 2\u2019-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia\/lymphomas","volume":"10","author":"Aldinucci","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.115184_bib229","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvw203","article-title":"Increased activity of vascular adenosine deaminase in atherosclerosis and therapeutic potential of its inhibition","volume":"112","author":"Kutryb-Zajac","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2023.115184_bib230","doi-asserted-by":"crossref","unstructured":"E. Kowalczyk, M. Kopff, J. Kowalski, A. Kopff, D.P. Mikhailidis, M. Barylski, M. Banach, Effect of Cardiovascular Drugs on Adenosine Deaminase Activity, Https:\/\/Doi.Org\/10.1177\/0003319708323495. 59 (2008) 740\u2013744. https:\/\/doi.org\/10.1177\/0003319708323495.","DOI":"10.1177\/0003319708323495"},{"key":"10.1016\/j.biopha.2023.115184_bib231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib232","doi-asserted-by":"crossref","first-page":"E1239","DOI":"10.1073\/pnas.1718197115","article-title":"Chemotherapy induces enrichment of CD47+\/CD73+\/PDL1+ immune evasive triple-negative breast cancer cells","volume":"115","author":"Samanta","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.115184_bib233","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-3-642-16483-5_89","article-title":"Adenosine and tumor microenvironment","author":"Blay","year":"2011","journal-title":"Encycl. Cancer"},{"key":"10.1016\/j.biopha.2023.115184_bib234","first-page":"177","article-title":"Purinergic regulation of the immune system","volume":"16","author":"Cekic","year":"2016","journal-title":"Nat. Rev. Immunol. 2016 163"},{"key":"10.1016\/j.biopha.2023.115184_bib235","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00262-011-1155-7","article-title":"Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor","volume":"61","author":"Waickman","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2023.115184_bib236","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11302-021-09775-w","article-title":"Influence of NSAIDs and methotrexate on CD73 expression and glioma cell growth","volume":"17","author":"Lopes","year":"2021","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.biopha.2023.115184_bib237","doi-asserted-by":"crossref","unstructured":"P.T.R. Rajagopalan, Z. Zhang, L. McCourt, M. Dwyer, S.J. Benkovic, G.G. Hammes, Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13481. https:\/\/doi.org\/10.1073\/PNAS.172501499.","DOI":"10.1073\/pnas.172501499"},{"key":"10.1016\/j.biopha.2023.115184_bib238","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0889-857X(05)70358-6","article-title":"The mechanism of action of methotrexate","volume":"23","author":"Cronstein","year":"1997","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.biopha.2023.115184_bib239","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.3390\/ijms21103483","article-title":"Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers","volume":"21","author":"Ko\u017ami\u0144ski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib240","first-page":"293","article-title":"Cancer chemotherapy: targeting folic acid synthesis","volume":"2","author":"Hagner","year":"2010","journal-title":"Cancer Manag. Res"},{"key":"10.1016\/j.biopha.2023.115184_bib241","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205023","article-title":"Methotrexate an old drug with new tricks","volume":"20","author":"Bedoui","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115184_bib242","first-page":"16","article-title":"Methotrexate in rheumatoid arthritis: a quarter century of development","volume":"124","author":"Weinblatt","year":"2013","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"10.1016\/j.biopha.2023.115184_bib243","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11302-016-9505-8","article-title":"Methotrexate up-regulates ecto-5\u2032-nucleotidase\/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment","volume":"12","author":"Figueir\u00f3","year":"2016","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.biopha.2023.115184_bib244","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","article-title":"Methotrexate mechanism in treatment of rheumatoid arthritis","volume":"86","author":"Friedman","year":"2019","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.biopha.2023.115184_bib245","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1042\/bj2810631","article-title":"Stimulus-response uncoupling in the neutrophil: Adenosine A2-receptor occupancy inhibits the sustained, but not the early, events of stimulus transduction in human neutrophils by a mechanism independent of actin-filament formation","volume":"281","author":"Cronstein","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2023.115184_bib246","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1172\/JCI112638","article-title":"Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells","volume":"78","author":"Cronstein","year":"1986","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2023.115184_bib247","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2567.2009.03075.x","article-title":"Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling","volume":"128","author":"Linnemann","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2023.115184_bib248","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/157015911795596559","article-title":"Nuclear factor \u03baB and adenosine receptors: biochemical and behavioral profiling","volume":"9","author":"Xie","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib249","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.bjp.0702040","article-title":"Suppression of macrophage inflammatory protein (MIP)-1\u03b1 production and collagen-induced arthritis by adenosine receptor agonists","volume":"125","author":"Szab\u00f3","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib250","first-page":"1308","article-title":"Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes. A mechanism for methotrexate-induced nodulosis in rheumatoid arthritis","author":"Monocytes","year":"1997","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.biopha.2023.115184_bib251","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1084\/jem.188.8.1433","article-title":"Neutrophil-derived 5\u2019-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation","volume":"188","author":"Lennon","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib252","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.1424792112","article-title":"Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis","volume":"112","author":"Peres","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.115184_bib253","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/1756-185X.13333","article-title":"CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis","volume":"21","author":"Gupta","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.biopha.2023.115184_bib254","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.17165","article-title":"Methotrexate activated Tregs via the CD73\/AMPK\/mTOR pathway","volume":"179","author":"Yan","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.biopha.2023.115184_bib255","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11302-012-9309-4","article-title":"Cellular function and molecular structure of ecto-nucleotidases","volume":"8","author":"Zimmermann","year":"2012","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.biopha.2023.115184_bib256","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114322","article-title":"History of ectonucleotidases and their role in purinergic signaling","volume":"187","author":"Zimmermann","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib257","doi-asserted-by":"crossref","DOI":"10.3390\/biology11050675","article-title":"Differences in extracellular NAD + and NMN metabolism on the surface of vascular endothelial cells","volume":"11","author":"Jablonska","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.biopha.2023.115184_bib258","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.imlet.2018.03.007","article-title":"Canonical and non-canonical adenosinergic pathways","volume":"205","author":"Ferretti","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.biopha.2023.115184_bib259","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1399-0039.1990.tb01750.x","article-title":"Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5\u2032-nucleotidase (CD73)","volume":"35","author":"Thomson","year":"1990","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.biopha.2023.115184_bib260","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.115184_bib261","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.pharep.2015.05.002","article-title":"The role of ecto-5\u2032-nucleotidase in endothelial dysfunction and vascular pathologies","volume":"67","author":"Zukowska","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biopha.2023.115184_bib262","doi-asserted-by":"crossref","DOI":"10.3390\/biom12050697","article-title":"Lack of ecto-5\u2032-nucleotidase protects sensitized mice against allergen challenge","author":"Caiazzo","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2023.115184_bib263","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cvr\/28.1.100","article-title":"Endothelial nucleotide catabolism and adenosine production","volume":"28","author":"Smolenski","year":"1994","journal-title":"Cardiovasc. Res"},{"key":"10.1016\/j.biopha.2023.115184_bib264","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-065X.1998.tb01574.x","article-title":"Ecto-enzyme and signaling functions of lymphocyte CD 7 3","volume":"161","author":"Resta","year":"1998","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biopha.2023.115184_bib265","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11302-005-5302-5","article-title":"Physiological roles for ecto-5\u2032-nucleotidase (CD73)","volume":"2","author":"Colgan","year":"2006","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.biopha.2023.115184_bib266","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1042\/bj2820181","article-title":"Modulation of 5\u2032-nucleotidase activity in plasma membranes and intact cells by the extracellular matrix proteins laminin and fibronectin","volume":"282","author":"Olmo","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2023.115184_bib267","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.cmr.0000215030.69823.11","article-title":"Expression of ecto-5\u2032-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma","volume":"16","author":"Sadej","year":"2006","journal-title":"Melanoma Res."},{"key":"10.1016\/j.biopha.2023.115184_bib268","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.4049\/jimmunol.165.10.5411","article-title":"CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism","volume":"165","author":"Airas","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2023.115184_bib269","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3389\/fimmu.2019.01729","article-title":"Generation and function of non-cell-bound cd73 in inflammation","volume":"10","author":"Schneider","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.115184_bib270","doi-asserted-by":"crossref","unstructured":"A.I. Su, T. Wiltshire, S. Batalov, H. Lapp, K.A. Ching, D. Block, J. Zhang, R. Soden, M. Hayakawa, G. Kreiman, M.P. Cooke, J.R. Walker, J.B. Hogenesch, A gene atlas of the mouse and human protein-encoding transcriptomes, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 6062\u20136067. https:\/\/doi.org\/10.1073\/PNAS.0400782101\/SUPPL_FILE\/00782FIG5.PDF.","DOI":"10.1073\/pnas.0400782101"},{"issue":"2014","key":"10.1016\/j.biopha.2023.115184_bib271","article-title":"The roles of CD73 in cancer","author":"Gao","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.biopha.2023.115184_bib272","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/cancers13020177","article-title":"CD73, tumor plasticity and immune evasion in solid cancers","volume":"13","author":"Yang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.115184_bib273","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/bjc.2012.95","article-title":"NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity","volume":"106","author":"Wang","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2023.115184_bib274","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2015.10.003","article-title":"CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis","author":"Kosza\u0142ka","year":"2015","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.biopha.2023.115184_bib275","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1158\/0008-5472.CAN-10-4246","article-title":"CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis","volume":"71","author":"Stagg","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.115184_bib276","first-page":"254","article-title":"The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy","volume":"14","author":"Jiang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.115184_bib277","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1074\/jbc.M109.047423","article-title":"Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells","volume":"285","author":"Mandapathil","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.115184_bib278","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.tcb.2021.05.008","article-title":"The elegant complexity of mammalian ecto-5\u2019-nucleotidase (CD73)","volume":"31","author":"Alcedo","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.biopha.2023.115184_bib279","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.115184_bib280","first-page":"5260","article-title":"Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.115184_bib281","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004089","article-title":"Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy","volume":"10","author":"Augustin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.115184_bib282","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1208875","article-title":"Targeting CD73 in the tumor microenvironment with MEDI9447","volume":"5","author":"Hay","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2023.115184_bib283","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s10147-022-02242-5","article-title":"Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study","volume":"27","author":"Kondo","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115184_bib284","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9047","article-title":"Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab \u00b1 durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).","volume":"39","author":"Bendell","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115184_bib285","first-page":"75","article-title":"Immunotherapy for triple-negative breast cancer: a molecular insight into the microenvironment, treatment, and resistance","volume":"1","author":"Bai","year":"2021","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.biopha.2023.115184_bib286","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung","volume":"40","author":"Herbst","year":"2022","journal-title":"Cancer J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115184_bib287","article-title":"CD73 inhibitor oleclumab plus osimertinib in previously treated patients with advanced T790M-negative EGFR-mutated NSCLC: a brief report","author":"Kim","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biopha.2023.115184_bib288","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000610","article-title":"Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade","volume":"8","author":"Yang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.115184_bib289","doi-asserted-by":"crossref","unstructured":"G. Griguolo, A. Tosi, V. Guarneri, M.V. Dieci, S. Fineberg, A. Ventura, L. Bauchet, J. Jacob, V. Rigau, W. Jacot, A. Rosato, A. Darlix, P. Conte, Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases., Https:\/\/Doi.Org\/10.1200\/JCO.2021.39.15_suppl.2021. 39 (2021) 2021\u20132021. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_SUPPL.2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.2021"},{"key":"10.1016\/j.biopha.2023.115184_bib290","doi-asserted-by":"crossref","unstructured":"B. Markman, A.H.-C. Hsieh, J. Coward, M.S. Carlino, S. Frentzas, X. Jin, B. Li, Z.M. Wang, K.Y. Kwek, Y. Xia, A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1\/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors., Https:\/\/Doi.Org\/10.1200\/JCO.2021.39.15_suppl.TPS2675. 39 (2021) TPS2675\u2013TPS2675. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_SUPPL.TPS2675.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2675"},{"key":"10.1016\/j.biopha.2023.115184_bib291","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5483\/BMBRep.2021.54.1.242","article-title":"Update of early phase clinical trials in cancer immunotherapy","volume":"54","author":"Lee","year":"2021","journal-title":"BMB Rep."},{"key":"10.1016\/j.biopha.2023.115184_bib292","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-CT180","article-title":"Abstract CT180:preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors","volume":"78","author":"Siu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.115184_bib293","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005802","article-title":"Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer","volume":"10","author":"Miller","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.115184_bib294","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005267","article-title":"Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-\u03b2-trap bifunctional antibody, in patients with advanced solid tumors","volume":"11","author":"Tolcher","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.115184_bib295","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/pharmrev.121.000528","article-title":"ATP and adenosine metabolism in cancer: exploitation for therapeutic gain","volume":"74","author":"Yegutkin","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2023.115184_bib296","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1535-7163.MCT-21-0802","article-title":"Targeting CD73 with AB680 (Quemliclustat), a novel and potent small-molecule CD73 inhibitor, restores immune functionality and facilitates antitumor immunity","volume":"21","author":"Piovesan","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2023.115184_bib297","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJM199112053252306","article-title":"Adenosine and supraventricular tachycardia","volume":"325","author":"Camm","year":"1991","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib298","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.724161","article-title":"Encephalopathy in preterm infants: advances in neuroprotection with caffeine","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.biopha.2023.115184_bib299","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1183\/09031936.95.08060996","article-title":"Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma","volume":"8","author":"Banner","year":"1995","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2023.115184_bib300","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/B978-0-323-24485-5.00077-2","article-title":"Aminophylline","author":"Papich","year":"2016","journal-title":"Saunders Handb. Vet. Drugs"},{"key":"10.1016\/j.biopha.2023.115184_bib301","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1021\/acs.jmedchem.8b01662","article-title":"Design and in vivo characterization of A 1 adenosine receptor agonists in the native ribose and conformationally constrained (N)-methanocarba series","volume":"62","author":"Tosh","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2023.115184_bib302","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fncel.2019.00124","article-title":"Historical and current adenosine receptor agonists in preclinical and clinical development","volume":"13","author":"Jacobson","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.biopha.2023.115184_bib303","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.yjmcc.2007.08.014","article-title":"Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse","volume":"43","author":"Salloum","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2023.115184_bib304","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson\u2019s disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.biopha.2023.115184_bib305","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2125.1987.tb03194.x","article-title":"Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man","volume":"24","author":"Gregov","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115184_bib306","article-title":"Dipyridamole myocardial perfusion imaging","volume":"35","author":"Leppo","year":"1994","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib307","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bcp.12220","article-title":"Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon","volume":"77","author":"Verhoef","year":"2014","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.115184_bib308","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003495-199958030-00007","article-title":"Extended-release dipyridamole\/aspirin","volume":"58","author":"Hervey","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2023.115184_bib309","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2016-03-707844","article-title":"Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor","volume":"128","author":"Aungraheeta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115184_bib310","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejphar.2009.04.017","article-title":"Inhibitory effect of nonsteroidal anti-inflammatory drugs on adenosine transport in vascular smooth muscle cells","volume":"612","author":"Li","year":"2009","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2023.115184_bib311","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/CIRCULATIONAHA.110.963843","article-title":"Aspirin","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115184_bib312","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.2","article-title":"The history of the use of sulphasalazine in rheumatology","author":"Amos","year":"1995","journal-title":"Rheumatology"},{"key":"10.1016\/j.biopha.2023.115184_bib313","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jamainternmed.2020.0099","article-title":"The skyrocketing cost of rectal indomethacin","volume":"180","author":"Elmunzer","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib314","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJM197504172921607","article-title":"New approaches to cancer chemotherapy with methotrexate","volume":"292","author":"Bleich","year":"1975","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115184_bib315","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis: Consensus conference","volume":"38","author":"Roenigk","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.biopha.2023.115184_bib316","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113074","article-title":"Application and pharmacological mechanism of methotrexate in rheumatoid arthritis","volume":"150","author":"Zhao","year":"2022","journal-title":"Biomed. Pharmacother."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223009757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223009757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:59:21Z","timestamp":1777877961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223009757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":316,"alternative-id":["S0753332223009757"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115184","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs targeting adenosine signaling pathways: A current view","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115184"}}